Upfront surgery for advanced ovarian cancer failed to improve overall survival (OS) versus interval debulking but did improve ...

Ovarian cancer isn't silent - learn the early warning signs. Persistent bloating, pelvic pain, urinary symptoms revealed.

Primary surgery for advanced ovarian cancer significantly improves progression-free survival but not overall survival ...

In addition, mirvetuximab soravtansine (Elahere) was the first targeted therapy to demonstrate an improvement in OS in ...

Brian Slomovitz, MD, of Mount Sinai Medical Center, compares relacorilant plus nab-paclitaxel with existing treatments for platinum-resistant ovarian cancer and highlights the ROSELLA trial’s global ...

Adding relacorilant to nab-paclitaxel improved survival outcomes in patients with platinum-resistant ovarian cancer.

Ovarian cancer is one of those. Ovarian cancer starts in the ovaries, which are two small glands located on either side of ...

Relacorilant/nab-paclitaxel significantly improved PFS and OS vs nab-paclitaxel alone in platinum-resistant ovarian cancer.

Around one in 10 women will develop ovarian cysts at some point during their lives, and while the prospect of a cyst growing ...